GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioiasis AD (XBUL:BIOA) » Definitions » Debt-to-EBITDA

Bioiasis AD (XBUL:BIOA) Debt-to-EBITDA : -138.74 (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Bioiasis AD Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioiasis AD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was лв4.11 Mil. Bioiasis AD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was лв9.76 Mil. Bioiasis AD's annualized EBITDA for the quarter that ended in Sep. 2023 was лв-0.10 Mil. Bioiasis AD's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -138.74.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bioiasis AD's Debt-to-EBITDA or its related term are showing as below:

XBUL:BIOA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -97.7   Med: 0.02   Max: 0.24
Current: -97.7

During the past 13 years, the highest Debt-to-EBITDA Ratio of Bioiasis AD was 0.24. The lowest was -97.70. And the median was 0.02.

XBUL:BIOA's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.26 vs XBUL:BIOA: -97.70

Bioiasis AD Debt-to-EBITDA Historical Data

The historical data trend for Bioiasis AD's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioiasis AD Debt-to-EBITDA Chart

Bioiasis AD Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioiasis AD Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -139.91 -138.74

Competitive Comparison of Bioiasis AD's Debt-to-EBITDA

For the Medical Devices subindustry, Bioiasis AD's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioiasis AD's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioiasis AD's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bioiasis AD's Debt-to-EBITDA falls into.



Bioiasis AD Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioiasis AD's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.075
=0.00

Bioiasis AD's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.112 + 9.762) / -0.1
=-138.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Bioiasis AD  (XBUL:BIOA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bioiasis AD Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bioiasis AD's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioiasis AD (XBUL:BIOA) Business Description

Traded in Other Exchanges
N/A
Address
60, Deyan Belishki Str., Ground Floor, Sofia, BGR, 1404
Bioiasis AD provides specialized medical devices, equipment, and consultation services to state and private hospitals and trading companies. The company also deals in Interventional Cardiology and General Surgery consumables.

Bioiasis AD (XBUL:BIOA) Headlines

No Headlines